Effects of arsenic exposure on DNA methylation and epigenetic gene regulation

Epigenomics

Volumn 2, Issue 1, 2010, Pages 87-104

  Reichard, John F ^a   Puga, Alvaro ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

arsenate; arsenic; arsenite; cancer; carcinogenesis; DNMT; epigenetics; glutathione; hypermethylation; hypomethylation; oxidative stress; S adenosylmethionine; SAM; transsulfuration

Indexed keywords

ARSENIC; DNA METHYLTRANSFERASE 1; FOLIC ACID; METHIONINE; METHIONINE ADENOSYLTRANSFERASE;

CARCINOGENESIS; CELL TRANSFORMATION; DESULFURIZATION; DNA METHYLATION; EPIGENETICS; GENE CONTROL; GENE DISRUPTION; GENE EXPRESSION; GENE LOCUS; GENE REPRESSION; GENE SILENCING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LONG TERM EXPOSURE; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; ARSENATES; ARSENIC; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; HUMANS; METHYLTRANSFERASES; MICE; NEOPLASMS; NUTRITIONAL PHYSIOLOGICAL PHENOMENA; OXIDATION-REDUCTION; OXIDATIVE STRESS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 77954107743     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.09.45     Document Type: Review

References (111)

1. Chen CJ, Kuo TL, Wu MM: Arsenic and cancers. Lancet 1(8582), 414-415 (1988).
2. Smith AH, Hopenhayn-Rich C, Bates MN et al.: Cancer risks from arsenic in drinking water. Environ. Health Perspect. 97, 259-267 (1992).
3. Hopenhayn-Rich C, Biggs ML, Fuchs A et al.: Bladder cancer mortality associated with arsenic in drinking water in Argentina. Epidemiology 7(2), 117-124 (1996).
4. Marshall G, Ferreccio C, Yuan Y et al.: Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. J. Natl Cancer Inst. 99(12), 920-928 (2007).
5. Smith AH, Marshall G, Yuan Y et al.: Increased mortality from lung cancer and bronchiectasis in young adults after exposure to arsenic in utero and in early childhood. Environ. Health Perspect. 114(8), 1293-1296 (2006).
6. Yuan Y, Marshall G, Ferreccio C et al.: Acute myocardial infarction mortality in comparison with lung and bladder cancer mortality in arsenic-exposed region II of Chile from 1950 to 2000. Am. J. Epidemiol. 166(12), 1381-1391 (2007).
7. Kumagai Y, Sumi D: Arsenic: signal transduction, transcription factor, and biotransformation involved in cellular response and toxicity. Annu. Rev. Pharmacol. Toxicol. 47, 243-262 (2007).
8. Gebel TW: Genotoxicity of arsenical compounds. Int. J. Hyg. Environ. Health 203(3), 249-262 (2001).
9. Hei TK, Filipic M: Role of oxidative damage in the genotoxicity of arsenic. Free Radic. Biol. Med. 37(5), 574-581 (2004).
10. Hughes MF: Arsenic toxicity and potential mechanisms of action. Toxicol. Lett. 133(1), 1-16 (2002).
11. Huang C, Ke Q, Costa M, Shi X: Molecular mechanisms of arsenic carcinogenesis. Mol. Cell. Biochem. 255(1-2), 57-66 (2004).
12. Rossman TG: Mechanism of arsenic carcinogenesis: an integrated approach. Mutat. Res. 533(1-2), 37-65 (2003).
13. Klein CB, Leszczynska J, Hickey C, Rossman TG: Further evidence against a direct genotoxic mode of action for arsenic-induced cancer. Toxicol. Appl. Pharmacol. 222(3), 289-297 (2007).
14. Cohen SM, Arnold LL, Eldan M, Lewis AS, Beck BD: Methylated arsenicals: the implications of metabolism and carcinogenicity studies in rodents to human risk assessment. Crit. Rev. Toxicol. 36(2), 99-133 (2006).
15. Kitchin KT: Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol. Appl. Pharmacol. 172(3), 249-261 (2001).
16. Waalkes MP, Liu J, Ward JM, Diwan BA: Animal models for arsenic carcinogenesis: inorganic arsenic is a transplacental carcinogen in mice. Toxicol. Appl. Pharmacol. 198(3), 377-384 (2004).
17. Rossman TG, Uddin AN, Burns FJ: Evidence that arsenite acts as a cocarcinogen in skin cancer. Toxicol. Appl. Pharmacol. 198(3), 394-404 (2004).
18. Nanney DL: Epigenetic control systems. Proc. Natl Acad. Sci. USA 44(7), 712-717 (1958).
19. Tang WY, Ho SM: Epigenetic reprogramming and imprinting in origins of disease. Rev. Endocr. Metab. Disord. 8(2), 173-182 (2007).
20. Mass MJ, Wang L: Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis. Mutat. Res. 386(3), 263-277 (1997).
21. Fouse SD, Shen Y, Pellegrini M et al.: Promoter CpG methylation contributes to ES cell gene regulation in parallel with Oct4/Nanog, PcG complex, and histone H3 K4/K27 trimethylation. Cell Stem Cell 2(2), 160-169 (2008).
22. Meissner A, Mikkelsen TS, Gu H et al.: Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454(7205), 766-770 (2008).
23. Herceg Z: Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors. Mutagenesis 22(2), 91-103 (2007).
24. de Bustros A, Nelkin BD, Silverman A, Ehrlich G, Poiesz B, Baylin SB: The short arm of chromosome 11 is a 'hot spot' for hypermethylation in human neoplasia. Proc. Natl Acad. Sci. USA 85(15), 5693-5697 (1988).
25. Laird PW, Jaenisch R: DNA methylation and cancer. Hum. Mol. Genet. 3(Spec. No.), 1487-1495 (1994).
26. Palii SS, Robertson KD: Epigenetic control of tumor suppression. Crit. Rev. Eukaryot. Gene Expr. 17(4), 295-316 (2007).
27. Gama-Sosa MA, Slagel VA, Trewyn RW et al.: The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res. 11(19), 6883-6894 (1983).
28. Diala ES, Cheah MS, Rowitch D, Hoffman RM: Extent of DNA methylation in human tumor cells. J. Natl Cancer Inst. 71(4), 755-764 (1983).
29. Almeida A, Kokalj-Vokac N, Lefrancois D et al.: Hypomethylation of classical satellite DNA and chromosome instability in lymphoblastoid cell lines. Hum. Genet. 91(6), 538-546 (1993).
30. Trinh BN, Long TI, Nickel AE, Shibata D, Laird PW: DNA methyltransferase defciency modifes cancer susceptibility in mice lacking DNA mismatch repair. Mol. Cell. Biol. 22(9), 2906-2917 (2002).
31. Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R: DNA hypomethylation leads to elevated mutation rates. Nature 395(6697), 89-93 (1998).
32. Maloisel L, Rossignol JL: Suppression of crossing-over by DNA methylation in Ascobolus. Genes Dev. 12(9), 1381-1389 (1998).
33. Bestor TH: The DNA methyltransferases of mammals. Hum. Mol. Genet. 9(16), 2395-2402 (2000).
34. Vahter M, Envall J: In vivo reduction of arsenate in mice and rabbits. Environ. Res. 32(1), 14-24 (1983).
35. Csanaky I, Gregus Z: Role of glutathione in reduction of arsenate and of g-glutamyltranspeptidase in disposition of arsenite in rats. Toxicology 207(1), 91-104 (2005).
36. Vahter M: Mechanisms of arsenic biotransformation. Toxicology 181-182, 211-217 (2002).
37. Hughes MF, Kenyon EM, Edwards BC, Mitchell CT, Razo LM, Thomas DJ: Accumulation and metabolism of arsenic in mice after repeated oral administration of arsenate. Toxicol. Appl. Pharmacol. 191(3), 202-210 (2003).
38. Drobna Z, Waters SB, Devesa V, Harmon AW, Thomas DJ, Styblo M: Metabolism and toxicity of arsenic in human urothelial cells expressing rat arsenic (+3 oxidation state)-methyltransferase. Toxicol. Appl. Pharmacol. 207(2), 147-159 (2005).
39. Gregus Z, Roos G, Geerlings P, Nemeti B: Mechanism of thiol-supported arsenate reduction mediated by phosphorolytic-arsenolytic enzymes: II. Enzymatic formation of arsenylated products susceptible for reduction to arsenite by thiols. Toxicol. Sci. 110(2), 282-292 (2009).
40. Gregus Z, Nemeti B: Purine nucleoside phosphorylase as a cytosolic arsenate reductase. Toxicol. Sci. 70(1), 13-19 (2002).
41. Nemeti B, Gregus Z: Glutathione-dependent reduction of arsenate by glycogen phosphorylase a reaction coupled to glycogenolysis. Toxicol. Sci. 100(1), 36-43 (2007). (Pubitemid 47617801)
42. Nemeti B, Gregus Z: Glutathione-supported arsenate reduction coupled to arsenolysis catalyzed by ornithine carbamoyl transferase. Toxicol. Appl. Pharmacol. 239(2), 154-161 (2009).
43. Thomas DJ, Li J, Waters SB et al.: Arsenic (+3 oxidation state) methyltransferase and the methylation of arsenicals. Exp. Biol. Med. 232(1), 3-13 (2007).
44. Thomas DJ, Waters SB, Styblo M: Elucidating the pathway for arsenic methylation. Toxicol. Appl. Pharmacol. 198(3), 319-326 (2004).
45. Zakharyan RA, Sampayo-Reyes A, Healy SM et al.: Human monomethylarsonic acid (MMA[V]) reductase is a member of the glutathione-S-transferase superfamily. Chem. Res. Toxicol. 14(8), 1051-1057 (2001).
46. Aposhian HV, Zakharyan RA, Avram MD, Sampayo-Reyes A, Wollenberg ML: A review of the enzymology of arsenic metabolism and a new potential role of hydrogen peroxide in the detoxication of the trivalent arsenic species. Toxicol. Appl. Pharmacol. 198(3), 327-335 (2004).
47. Waters SB, Devesa V, Fricke MW, Creed JT, Styblo M, Thomas DJ: Glutathione modulates recombinant rat arsenic (+3 oxidation state) methyltransferase-catalyzed formation of trimethylarsine oxide and trimethylarsine. Chem. Res. Toxicol. 17(12), 1621-1629 (2004).
48. Vahter M: Effects of arsenic on maternal and fetal health. Annu. Rev. Nutr. 29, 381-399 (2009).
49. Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MP: Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc. Natl Acad. Sci. USA 94(20), 10907-10912 (1997).
50. Reichard JF, Schnekenburger M, Puga A: Long term low-dose arsenic exposure induces loss of DNA methylation. Biochem. Biophys. Res. Commun. 352(1), 188-192 (2007).
51. Coppin JF, Qu W, Waalkes MP: Interplay between cellular methyl metabolism and adaptive effux during oncogenic transformation from chronic arsenic exposure in human cells. J. Biol. Chem. 283(28), 19342-19350 (2008).
52. Caudill MA, Wang JC, Melnyk S et al.: Intracellular S- adenosylhomocysteine concentrations predict global DNA hypomethylation in tissues of methyl-defcient cystathionine b-synthase heterozygous mice. J. Nutr. 131(11), 2811-2818 (2001).
53. Hoffman DR, Marion DW, Cornatzer WE, Duerre JA: S-adenosylmethionine and S-adenosylhomocystein metabolism in isolated rat liver. Effects of l-methionine, l-homocystein, and adenosine. J. Biol. Chem. 255(22), 10822-10827 (1980).
54. Counts JL, Sarmiento JI, Harbison ML, Downing JC, McClain RM, Goodman JL: Cell proliferation and global methylation status changes in mouse liver after phenobarbital and/or choline-devoid, methionine-defcient diet administration. Carcinogenesis 17(6), 1251-1257 (1996).
55. Davis CD, Uthus EO: DNA methylation, cancer susceptibility, and nutrient interactions. Exp. Biol. Med. (Maywood) 229(10), 988-995 (2004).
56. Waterland RA, Jirtle RL: Early nutrition, epigenetic changes at transposons and imprinted genes, and enhanced susceptibility to adult chronic diseases. Nutrition 20(1), 63-68 (2004).
57. Hitchler MJ, Domann FE: An epigenetic perspective on the free radical theory of development. Free Radic. Biol. Med. 43(7), 1023-1036 (2007).
58. Allen RG, Balin AK: Oxidative infuence on development and differentiation: an overview of a free radical theory of development. Free Radic. Biol. Med. 6(6), 631-661 (1989).
59. Kann S, Estes C, Reichard JF et al.: Butylhydroquinone protects cells genetically defcient in glutathione biosynthesis from arsenite-induced apoptosis without signifcantly changing their prooxidant status. Toxicol. Sci. 87(2), 365-384 (2005).
60. Zheng XH, Watts GS, Vaught S, Gandolf AJ: Low-level arsenite induced gene expression in HEK293 cells. Toxicology 187(1), 39-48 (2003).
61. Lertratanangkoon K, Orkiszewski RS, Scimeca JM: Methyl-donor defciency due to chemically induced glutathione depletion. Cancer Res. 56(5), 995-1005 (1996).
62. Lertratanangkoon K, Wu CJ, Savaraj N, Thomas ML: Alterations of DNA methylation by glutathione depletion. Cancer Lett. 120(2), 149-156 (1997).
63. Spuches AM, Kruszyna HG, Rich AM, Wilcox DE: Thermodynamics of the As(III)-thiol interaction: arsenite and monomethylarsenite complexes with glutathione, dihydrolipoic acid, and other thiol ligands. Inorg. Chem. 44(8), 2964-2972 (2005).
64. Kann S, Huang MY, Estes C et al.: Arsenite-induced aryl hydrocarbon receptor nuclear translocation results in additive induction of phase I genes and synergistic induction of phase II genes. Mol. Pharmacol. 68(2), 336-346 (2005).
65. Hermann A, Gowher H, Jeltsch A: Biochemistry and biology of mammalian DNA methyltransferases. Cell. Mol. Life Sci. 61(19-20), 2571-2587 (2004).
66. Jeltsch A: On the enzymatic properties of Dnmt1: specifcity, processivity, mechanism of linear diffusion and allosteric regulation of the enzyme. Epigenetics 1(2), 63-66 (2006).
67. Grandjean V, Yaman R, Cuzin F, Rassoulzadegan M: Inheritance of an epigenetic mark: the CpG DNA methyltransferase 1 is required for de novo establishment of a complex pattern of non-CpG methylation. PLoS ONE 2(11), E1136 (2007).
68. Feltus FA, Lee EK, Costello JF, Plass C, Vertino PM: Predicting aberrant CpG island methylation. Proc. Natl Acad. Sci. USA 100(21), 12253-12258 (2003).
69. Jair K W, Bachman KE, Suzuki H et al.: De novo CpG island methylation in human cancer cells. Cancer Res. 66(2), 682-692 (2006).
70. Benbrahim-Tallaa L, Waterland RA, Styblo M, Achanzar WE, Webber MM, Waalkes MP: Molecular events associated with arsenic-induced malignant transformation of human prostatic epithelial cells: aberrant genomic DNA methylation and K-ras oncogene activation. Toxicol. Appl. Pharmacol. 206(3), 288-298 (2005).
71. Cui X, Wakai T, Shirai Y, Yokoyama N, Hatakeyama K, Hirano S: Arsenic trioxide inhibits DNA methyltransferase and restores methylation-silenced genes in human liver cancer cells. Hum. Pathol. 37(3), 298-311 (2006).
72. Chanda S, Dasgupta UB, Guhamazumder D et al.: DNA hypermethylation of promoter of gene p53 and p16 in arsenic-exposed people with and without malignancy. Toxicol. Sci. 89(2), 431-437 (2006).
73. Marsit CJ, Karagas MR, Danaee H et al.: Carcinogen exposure and gene promoter hypermethylation in bladder cancer. Carcinogenesis 27(1), 112-116 (2006).
74. INK4a and RASSF1A and induces lung cancer in A/J mice. Toxicol. Sci. 91(2), 372-381 (2006).
75. Chen WT, Hung WC, Kang WY, Huang YC, Chai CY: Urothelial carcinomas arising in arsenic-contaminated areas are associated with hypermethylation of the gene promoter of the death-associated protein kinase. Histopathology 51(6), 785-792 (2007).
76. Jensen TJ, Novak P, Eblin KE, Gandolf AJ, Futscher BW: Epigenetic remodeling during arsenical-induced malignant transformation. Carcinogenesis 29(8), 1500-1508 (2008).
77. Balaghi M, Wagner C: DNA methylation in folate defciency: use of CpG methylase. Biochem. Biophys. Res. Commun. 193(3), 1184-1190 (1993).
78. Chen H, Liu J, Zhao CQ, Diwan BA, Merrick BA, Waalkes MP: Association of c-myc overexpression and hyperproliferation with arsenite-induced malignant transformation. Toxicol. Appl. Pharmacol. 175(3), 260-268 (2001).
79. Chen H, Liu J, Merrick BA, Waalkes MP: Genetic events associated with arsenic-induced malignant transformation: applications of cDNA microarray technology. Mol. Carcinog. 30(2), 79-87 (2001).
80. Liu J, Brahim-Tallaa L, Qian X et al.: Further studies on aberrant gene expression associated with arsenic-induced malignant transformation in rat liver TRL1215 cells. Toxicol. Appl. Pharmacol. 216(3), 407-415 (2006).
81. Chen H, Li S, Liu J, Diwan BA, Barrett JC, Waalkes MP: Chronic inorganic arsenic exposure induces hepatic global and individual gene hypomethylation: implications for arsenic hepatocarcinogenesis. Carcinogenesis 25(9), 1779-1786 (2004).
82. Waalkes MP, Liu J, Chen H et al.: Estrogen signaling in livers of male mice with hepatocellular carcinoma induced by exposure to arsenic in utero. J. Natl Cancer Inst. 96(6), 466-474 (2004).
83. Bates MN, Smith AH, Hopenhayn-Rich C: Arsenic ingestion and internal cancers: a review. Am. J. Epidemiol. 135(5), 462-476 (1992).
84. Rossman TG, Uddin AN, Burns FJ, Bosland MC: Arsenite is a cocarcinogen with solar ultraviolet radiation for mouse skin: an animal model for arsenic carcinogenesis. Toxicol. Appl. Pharmacol. 176(1), 64-71 (2001).
85. Germolec DR, Spalding J, Yu HS et al.: Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. Am. J. Pathol. 153(6), 1775-1785 (1998).
86. Xie Y, Trouba KJ, Liu J, Waalkes MP, Germolec DR: Biokinetics and subchronic toxic effects of oral arsenite, arsenate, monomethylarsonic acid, and dimethylarsinic acid in v-Ha-ras transgenic (Tg.AC) mice. Environ. Health Perspect. 112(12), 1255-1263 (2004).
87. Tennant RW, Spalding J, French JE: Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. Mutat. Res. 365(1-3), 119-127 (1996).
88. Spalding J W, Momma J, Elwell MR, Tennant RW: Chemically induced skin carcinogenesis in a transgenic mouse line (TG.AC) carrying a v-Ha-ras gene. Carcinogenesis 14(7), 1335-1341 (1993).
89. Thompson KL, Rosenzweig BA, Tsong Y, Sistare FD: Evaluation of in vitro reporter gene induction assays for use in a rapid prescreen for compound selection to test specifcity in the Tg.AC mouse short-term carcinogenicity assay. Toxicol. Sci. 57(1), 43-53 (2000).
90. Aschengrau A, Zierler S, Cohen A: Quality of community drinking water and the occurrence of spontaneous abortion. Arch. Environ. Health 44(5), 283-290 (1989).
91. Cherry N, Shaikh K, McDonald C, Chowdhury Z: Stillbirth in rural Bangladesh: arsenic exposure and other etiological factors: a report from Gonoshasthaya Kendra. Bull. World Health Organ. 86(3), 172-177 (2008).
92. Kwok RK, Kaufmann RB, Jakariya M: Arsenic in drinking-water and reproductive health outcomes: a study of participants in the Bangladesh Integrated Nutrition Programme. J. Health Popul. Nutr. 24(2), 190-205 (2006).
93. Lindgren A, Danielsson BR, Dencker L, Vahter M: Embryotoxicity of arsenite and arsenate: distribution in pregnant mice and monkeys and effects on embryonic cells in vitro. Acta Pharmacol. Toxicol. (Copenh.) 54(4), 311-320 (1984).
94. Concha G, Vogler G, Lezcano D, Nermell B, Vahter M: Exposure to inorganic arsenic metabolites during early human development. Toxicol. Sci. 44(2), 185-190 (1998).
95. Devesa V, Adair BM, Liu J et al.: Arsenicals in maternal and fetal mouse tissues after gestational exposure to arsenite. Toxicology 224(1-2), 147-155 (2006).
96. Liu L, Li Y, Tollefsbol TO: Gene-environment interactions and epigenetic basis of human diseases. Curr. Issues Mol. Biol. 10(1-2), 25-36 (2008).
97. Waalkes MP, Ward JM, Liu J, Diwan BA: Transplacental carcinogenicity of inorganic arsenic in the drinking water: induction of hepatic, ovarian, pulmonary, and adrenal tumors in mice. Toxicol. Appl. Pharmacol. 186(1), 7-17 (2003).
98. Waalkes MP, Liu J, Ward JM, Diwan BA: Mechanisms underlying arsenic carcinogenesis: hypersensitivity of mice exposed to inorganic arsenic during gestation. Toxicology 198(1-3), 31-38 (2004).
99. Ahlborn GJ, Nelson GM, Grindstaff RD et al.: Impact of life stage and duration of exposure on arsenic-induced proliferative lesions and neoplasia in C3H mice. Toxicology 262(2), 106-113 (2009).
100. Xie Y, Liu J, Brahim-Tallaa L et al.: Aberrant DNA methylation and gene expression in livers of newborn mice transplacentally exposed to a hepatocarcinogenic dose of inorganic arsenic. Toxicology 236(1-2), 7-15 (2007).
101. Majumdar S, Chanda S, Ganguli B, Mazumder DN, Lahiri S, Dasgupta UB: Arsenic exposure induces genomic hypermethylation. Environ. Toxicol. (2009) (Epub ahead of print). Goodman JI, Watson RE: Altered DNA methylation: a secondary mechanism involved in carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 42, 501-525 (2002).
102. Kisseljova NP, Kisseljov FL: DNA demethylation and carcinogenesis. Biochemistry (Mosc.) 70(7), 743-752 (2005).
103. Okoji RS, Yu RC, Maronpot RR, Froines JR: Sodium arsenite administration via drinking water increases genome-wide and Ha-ras DNA hypomethylation in methyl-defcient C57BL/6J mice. Carcinogenesis 23(5), 777-785 (2002).
104. Borrello MG, Pierotti MA, Tamborini E et al.: DNA methylation of coding and non-coding regions of the human H-RAS gene in normal and tumor tissues. Oncogene 7(2), 269-275 (1992).
105. Pilsner JR, Liu X, Ahsan H et al.: Genomic methylation of peripheral blood leukocyte DNA: infuences of arsenic and folate in Bangladeshi adults. Am. J. Clin. Nutr. 86(4), 1179-1186 (2007).
106. Pilsner JR, Liu X, Ahsan H et al.: Folate defciency, hyperhomocysteinemia, low urinary creatinine, and hypomethylation of leukocyte DNA are risk factors for arsenic-induced skin lesions. Environ. Health Perspect. 117(2), 254-260 (2009).
107. Shen L, Waterland RA: Methods of DNA methylation ana lysis. Curr. Opin. Clin. Nutr. Metab. Care 10(5), 576-581 (2007).
108. Zhou X, Sun H, Ellen TP, Chen H, Costa M: Arsenite alters global histone H3 methylation. Carcinogenesis 29(9), 1831-1836 (2008).
109. Jensen TJ, Wozniak RJ, Eblin KE, Wnek SM, Gandolf AJ, Futscher BW: Epigenetic mediated transcriptional activation of WNT5A participates in arsenical-associated malignant transformation. Toxicol. Appl. Pharmacol. 235(1), 39-46 (2009).
110. Pan G, Tian S, Nie J et al.: Whole-genome ana lysis of histone H3 lysine 4 and lysine 27 methylation in human embryonic stem cells. Cell Stem Cell 1(3), 299-312 (2007).
111. Uthus EO, Davis C: Dietary arsenic affects dimethylhydrazine-induced aberrant crypt formation and hepatic global DNA methylation and DNA methyltransferase activity in rats. Biol. Trace Elem. Res. 103(2), 133-145 (2005).